This article has been updated from a previous version to clarify that Illumina is developing technologies for drug development, not drugs.
SAN FRANCISCO, Jan. 8 - Illumina has signed an agreement with Johns Hopkins Medical University's Institute of Genetic Medicine to provide SNP genotyping services for a collection of samples provided by the Institute, the company said on Tuesday.
Terms of the agreement call for Illumina to use its BeadArray technology to score the frequency of specified SNPs in the set of samples linked to cleft lips and palates. The company will also design functional assays for most of the SNP loci.
Financial details of the partnership were not disclosed.
In a separate announcement, Jay Flatley, Illumina's president and CEO, said that his company intends by the end of the year to increase from 4,000 to 10,000 the number of array matrices it can manufacturer per year. He added that he hopes to build the infrastructure to allow it to double that capacity over the next year.
Outlining Illumina's genotyping goals for the new year, Flatley, speaking at the 20th annual JPMorgan H&Q Healthcare Conference here, said he expects to close 10 genotyping contracts in 2002 and to oversee the commercial launch of Illumina's genotyping technology.
He also said that a high-volume SNP-analysis product that Illumina has been working on in a collaboration with Applied Biosystems will be marketed mid-year. That product is based on Illumina's BeadArray technology and ABI's DNA chemistry.
In addition, Illumina officials said they are "solely developing" additional applications in genotyping as well as gene expression and proteomics.